- Home
- / Ocugen
Ocugen
Stock Price
$1
2024-10-29
Market Capitalization
$292.1 M
2024-10-29
Revenue
$4.4 M
FY, 2025
Ocugen Summary
Company Summary
- Overview
- Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies to treat eye diseases. Its modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- Malvern, PA, US | view all locations
- Website
- https://ocugen.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Kirsten M. Castillo, Director
Sanjay S. Subramanian, Chief Financial Officer
Prabhavathi Fernandes, Director
LocationsView all
1 location detected
Malvern, PA HQ
United States
5 Great Valley Pkwy #160
Ocugen Financials
Summary Financials
- Revenue (Q1, 2026)
- $1.5M
- Net income (Q1, 2026)
- ($19.2M)
- Cash (Q1, 2026)
- $31.9M
- EBIT (Q1, 2026)
- ($17.8M)
- Enterprise value
- $293.5M